By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against cancer cells in specific patient groups.
Ocugen (OCGN) came out with a quarterly loss of $0.05 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.06 per share a year ago. These figures are adjusted for ...
Scientists have identified new gene faults and evolutionary patterns contributing to testicular cancer. Their findings offer profound insights into the development of the disease and into potential ...